评估达格列净对2型糖尿病患者左心室舒张功能影响的随机对照试验：IDDIA试验 - Suppr

Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus: The IDDIA Trial.

作者信息

Shim Chi Young, Seo Jiwon, Cho Iksung, Lee Chan Joo, Cho In-Jeong, Lhagvasuren Purevjargal, Kang Seok-Min, Ha Jong-Won, Han Gyoonhee, Jang Yangsoo, Hong Geu-Ru

机构信息

Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (C.Y.S., J.S., I.C., C.J.L., S-M.K., J-W.H., Y.J., G-R.H.).

Division of Cardiology, Department of Internal Medicine, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Korea (I-J.C.).

出版信息

Circulation. 2021 Feb 2;143(5):510-512. doi: 10.1161/CIRCULATIONAHA.120.051992. Epub 2020 Nov 13.

DOI:10.1161/CIRCULATIONAHA.120.051992

PMID:33186508

Abstract

摘要

相似文献

Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus: The IDDIA Trial.

Circulation. 2021 Feb 2;143(5):510-512. doi: 10.1161/CIRCULATIONAHA.120.051992. Epub 2020 Nov 13.

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.

Cardiovasc Diabetol. 2018 Oct 8;17(1):132. doi: 10.1186/s12933-018-0775-z.

Dapagliflozin Suppresses ER Stress and Improves Subclinical Myocardial Function in Diabetes: From Bedside to Bench.

Diabetes. 2021 Jan;70(1):262-267. doi: 10.2337/db20-0840. Epub 2020 Oct 28.

Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.

Cardiovasc Diabetol. 2020 Jan 7;19(1):6. doi: 10.1186/s12933-019-0985-z.

Dapagliflozin (Farxiga) - a new indication for heart failure.

Med Lett Drugs Ther. 2020 Jun 29;62(1601):102-103.

Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.

Circulation. 2019 May 28;139(22):2528-2536. doi: 10.1161/CIRCULATIONAHA.119.040130. Epub 2019 Mar 18.

Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.

Cardiovasc Diabetol. 2021 Jan 7;20(1):6. doi: 10.1186/s12933-020-01175-5.

Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.

Diabetes Obes Metab. 2019 Feb;21(2):285-292. doi: 10.1111/dom.13520. Epub 2018 Oct 2.

Sodium glucose co-transporter 2 inhibitors in heart failure therapy.

Turk Kardiyol Dern Ars. 2020 Apr;48(3):330-354. doi: 10.5543/tkda.2020.74332.

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.

Circulation. 2019 Nov 19;140(21):1693-1702. doi: 10.1161/CIRCULATIONAHA.119.042375. Epub 2019 Aug 22.

引用本文的文献

Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomized controlled trials.

Eur Heart J Cardiovasc Pharmacother. 2025 Aug 12;11(5):441-450. doi: 10.1093/ehjcvp/pvaf040.

Shedding light on the effects of sodium-glucose cotransporter 2 inhibitors in the early stages of heart failure.

World J Cardiol. 2025 Mar 26;17(3):102893. doi: 10.4330/wjc.v17.i3.102893.

Is early use of sodium-glucose cotransporter type 2 inhibitor (SGLT2i) necessary even in diabetic patients without cardiovascular disease: a prospective study regarding the effect of SGLT2i on left ventricular diastolic function.

J Cardiovasc Imaging. 2025 Jan 13;33(1):1. doi: 10.1186/s44348-024-00043-0.

Leveraging metabolism for better outcomes in heart failure.

Cardiovasc Res. 2024 Dec 4;120(15):1835-1850. doi: 10.1093/cvr/cvae216.

Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial.

Cardiovasc Diabetol. 2024 Aug 28;23(1):319. doi: 10.1186/s12933-024-02344-6.

Effects of SGLT2 Inhibitors on Cardiac Mechanics in Hispanic and Black Diabetic Patients.

J Clin Med. 2024 Aug 4;13(15):4555. doi: 10.3390/jcm13154555.

Rationale and Design of Prospective, Multicenter, Double-Arm Clinical Trial to Investigate the Efficacy of Tofogliflozin on Left Ventricular Diastolic Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes Mellitus (TOP-HFPEF Trial).

Cardiovasc Drugs Ther. 2025 Feb;39(1):145-154. doi: 10.1007/s10557-024-07576-y. Epub 2024 May 10.

ELUCIDATE Trial: A Single-Center Randomized Controlled Study.

J Am Heart Assoc. 2024 May 7;13(9):e033832. doi: 10.1161/JAHA.123.033832. Epub 2024 Apr 19.

Effects of canagliflozin on cardiac remodeling and hemodynamic parameters in patients with type 2 diabetes mellitus.

Sci Rep. 2023 Dec 3;13(1):21327. doi: 10.1038/s41598-023-48716-y.

Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus.

Pharmaceutics. 2023 Oct 25;15(11):2526. doi: 10.3390/pharmaceutics15112526.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus: The IDDIA Trial.

作者信息

Shim Chi Young, Seo Jiwon, Cho Iksung, Lee Chan Joo, Cho In-Jeong, Lhagvasuren Purevjargal, Kang Seok-Min, Ha Jong-Won, Han Gyoonhee, Jang Yangsoo, Hong Geu-Ru

机构信息

Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea (C.Y.S., J.S., I.C., C.J.L., S-M.K., J-W.H., Y.J., G-R.H.).

Division of Cardiology, Department of Internal Medicine, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Korea (I-J.C.).

出版信息

Circulation. 2021 Feb 2;143(5):510-512. doi: 10.1161/CIRCULATIONAHA.120.051992. Epub 2020 Nov 13.

DOI:10.1161/CIRCULATIONAHA.120.051992

PMID:33186508

Abstract

摘要

Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus: The IDDIA Trial.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus: The IDDIA Trial.

作者信息

机构信息

出版信息

相似文献

引用本文的文献